Takeda Pharmaceutical Co. Ltd. has filed a prospectus with the Securities and Exchange Commission as part of a Registration Statement on Form F-3, in collaboration with Takeda U.S. Financing, Inc. The filing includes the issuance of $1.65 billion in 5.200% Guaranteed Notes due 2035 and $750 million in 5.900% Guaranteed Notes due 2055. The respective opinions on these financial instruments have been provided by Sullivan & Cromwell LLP and Nishimura & Asahi (Gaikokuho Kyodo Jigyo). The indenture, dated July 2, 2025, involves Takeda Pharmaceutical as the guarantor, Takeda U.S. Financing as the issuer, and The Bank of New York Mellon in various trustee and agent roles. This financial move is part of Takeda's strategic financing efforts, as detailed in their recent Form 6-K submission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.